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We have examined a series of 37 patients with histologically proved primary malignant melanoma for evidence of tumour-directed cellular immunity. Using the leucocyte migration technique we found evidence of such reactivity in 24/37 patients. Tests with control donors' leucocytes and control antigen preparations supported the specificity of the reaction. The histology of all tumours was carefully analysed using new criteria (Classification of Melanoma, Sydney 1972 . Cancer, N. Y., 1972 There have been a number of reports describing antibody to melanoma in approximately 60% of patients with melanoma. However, the technique and the site of fluorescence within the cell have varied.
Sera from melanoma patients were tested against 6 melanoma cell lines by immunofluorescence using cell smears. Results were analysed with regard to the pathological classification of the patients' tumour. No immunofluorescence was detected with sera from patients presenting with tumour restricted to the upper dermis, whereas up to 40% of patients wth tumour spread to the lower dermis were positive. Sera from patients with secondary melanoma showed a higher reactivity.
The cell lines varied in antigenicity and the lines which were most antigenic were also most reactive against normal sera.
If the results were analysed with regard to the number of sera reacting against at least one cell line, then 50% of primary melanoma sera and 90% of secondary melanoma sera were positive.
This indicates that the method of analysis is crucial to the final result, and the current status of serum immunity to melanoma is discussed in this context. Controversy still exists as to whether lymphocyte transformation to phytohaemagglutinin (PHA) is depressed in patients with non-lymphoid malignancies. The need to determine dose response curves in any patient with suspected immune deficiency has
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